References in periodicals archive ?
We assessed serological tests of HBsAg, HBsAb, HBeAg, HBeAb, HBcAb, and anti-HCV using Architect chemiluminescent enzyme immunoassays (Abbott Architect i system).
The most recent follow-up data for the patient is available at 2 years and 7 months from the acute episode, with the patient being in inactive HBsAg carrier state, (3) with liver function parameters remaining normal, still positive for HBsAg, but with undetectable HBV-DNA, negative HBeAg and positive HBeAb.
Extended markers consisted of the e antigen (HBeAg) and antibody (HBeAb) and IgM antibody to the core (HBcIM).
Patients who undergo seroconversion from HBeAg to HBeAb during lamivudine therapy may experience long-term remission, even after withdrawal of drug.
Blood cells (white blood cells, red blood cells, hemoglobin, and platelets), biochemical parameters (serum aspartate transaminase [AST], alanine transaminase [ALT], total bilirubin, blood urea nitrogen [BUN], and creatinine), virologic parameters (quantitative HBsAg, HBeAg, HBeAb, and HBV DNA), T lymphocytes (CD4 positive T lymphocytes [CD[4.sup.+]T], CD8 positive T lymphocytes [CD[8.sup.+]T], Type 1 helper T lymphocytes [Th1], and Type 2 helper T lymphocytes [Th2]), and ultrasound results were assessed at every visit.
Among them, one patient's HBeAb changed from negative to positive.
The fact that parameters such as HBsAb, Anti HBc IgG core total, HBeAg, HBeAb, AST, and ALT were not examined, and that the cases were not classified in detail (as acute or chronic hepatitis, active or inactive HBsAg carrier) are limitations of the study.
Some patients who undergo seroconversion to HBeAb maintain elevated ALT and HBV DNA levels and remain in, or revert to, an immune-active phase, sometimes called the immune escape phase of HBV disease.
Efficacy was evaluated based on the following criteria: alanine aminotransferase (ALT) normalization: ALT levels < 40 IU/ml; undetectable HBV DNA: HBV DNA levels < 1,000 copies/ml or less; HBeAg loss; HBeAg seroconversion: HBeAg loss and occurrence of HBeAb at the end of treatment (EOT).
All patients were screened for the presence of HBV surface antigen (HBsAg), surface antibody, e antigen (HBeAg), e antibody (HBeAb), core antibody (HBcAb), and HBV DNA load.
Markers of hepatitis B virus in mothers and vertical transmission of the virus Markers of HBV in HBV- mother HIV+ DNA HBsAg HBeAg A 5 + + + B 2 - + - C 7 - - - Vertical HBV HBsAb HBeAb HBcAb transmission A - - + 3 B - + - 0 C - - + 0
The indications for low-dose liver CT as an IHA tool in asymptomatic people for high-risk liver cancer in China include HBsAg (+), HBeAg (+), and HBcAb (+) or HBsAg (+), HBeAb (+), and HBcAb (+), with AFP more than 2 times of normal value.
Acronyms browser ?
Full browser ?
- HBEAG-binding protein 2-binding protein C
- HBEBP2-binding protein C